Osteoporosis Treatment: When to Discontinue and When to Re-start | Bone Research
Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review | SpringerLink
Relationship between denosumab doses number and delay to vertebral... | Download Scientific Diagram
Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review | SpringerLink
Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report - ScienceDirect
Incidence of vertebral and non-vertebral fractures in % (and number of... | Download Scientific Diagram
Denosumab: Mechanisms and Therapeutic Effects in the Treatment of Osteoporosis | SpringerLink
Can Rare Rebound Fractures After Denosumab Therapy Be Avoided?
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS - ScienceDirect
Observations following discontinuation of long-term denosumab therapy
DENOSUMAB
Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation - ScienceDirect
Long-term follow up after denosumab treatment for osteoporosis – rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report | Journal of Medical Case Reports
Frontiers | Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation
To Prevent Fractures, Get the Order of Osteoporosis Drugs Right, Study Says | Everyday Health
Long-term follow up after denosumab treatment for osteoporosis – rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report | Journal of Medical Case Reports
Long-term follow up after denosumab treatment for osteoporosis – rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report | Journal of Medical Case Reports
Frontiers | A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial
JCM | Free Full-Text | Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases - ScienceDirect
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension - Cummings - 2018 - Journal of Bone and Mineral Research - Wiley Online Library
Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report - ScienceDirect
Endocrinology and Metabolism
SAT0464 MULTIPLE REBOUND-ASSOCIATED VERTEBRAL FRACTURES AFTER DENOSUMAB DISCONTINUATION IN RHEUMATOLOGY CLINIC | Annals of the Rheumatic Diseases
How Long Can You Take Prolia Injections and Prolia Side Effects
Multiple vertebral fractures following discontinuation of denosumab treatment: ten clinical cases report | Reumatología Clínica
Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases - ScienceDirect
